Aspire-Lakewood Approves $10 Million Buyback and Completes Name Change from Aspire Biopharma
Aspire-Lakewood Holdings, Inc. filed a charter amendment changing its name from Aspire Biopharma Holdings, Inc., effective September 8, 2026, and its Board authorized a $10 million common stock repurchase program effective September 9, 2026. The company said the buyback reflects its view that its share price does not reflect its financial strength, and it cited the newly acquired Dura Control Systems Corp. (DCSC) as support.
Key points
- Board authorized a $10 million common stock repurchase program, effective September 9, 2026, with no expiration date and no required number of shares.
- Name change to Aspire-Lakewood Holdings, Inc. was effective September 8, 2026; no stockholder approval was required and the CUSIP is unchanged.
- The 8-K states the Nasdaq trading symbol remains ASPB, while the press release uses ASBP.
- DCSC reported audited 2025 revenue of approximately $209.5 million and Adjusted EBITDA of $22.3 million; unaudited six months ended June 30, 2026 revenue was approximately $103.9 million and Adjusted EBITDA $10.5 million.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.